Geneva, August 27, 2019 – Alcon (SIX/NYSE:ALC), the global leader in eye care, today announced the Food and Drug Administration (FDA) approval and its initial commercial launch of AcrySof®IQ PanOptix®Trifocal Intraocular Lens (IOL), the first and only trifocal lens for U.S. patients undergoing cataract surgery. PanOptix is clinically shown to deliver an exceptional combination of near, intermediate and distance vision while significantly reducing the need for glasses after surgery.

See video and press release below:

 

 

Alcon-Introduces-AcrySof-IQ-PanOptix-Trifocal-IOL-in-the-US-the-First-and-Only-FDA-Approved-Trifocal-Lens